Authors
Anatoly V Skalny, Lothar Rink, Olga P Ajsuvakova, Michael Aschner, Viktor A Gritsenko, Svetlana I Alekseenko, Andrey A Svistunov, Demetrios Petrakis, Demetrios A Spandidos, Jan Aaseth, Aristidis Tsatsakis, Alexey A Tinkov
Publication date
2020/7/1
Source
International journal of molecular medicine
Volume
46
Issue
1
Pages
17-26
Publisher
Spandidos Publications
Description
In view of the emerging COVID‑19 pandemic caused by SARS‑CoV‑2 virus, the search for potential protective and therapeutic antiviral strategies is of particular and urgent interest. Zinc is known to modulate antiviral and antibacterial immunity and regulate inflammatory response. Despite the lack of clinical data, certain indications suggest that modulation of zinc status may be beneficial in COVID‑19. In vitro experiments demonstrate that Zn2+ possesses antiviral activity through inhibition of SARS‑CoV RNA polymerase. This effect may underlie therapeutic efficiency of chloroquine known to act as zinc ionophore. Indirect evidence also indicates that Zn2+ may decrease the activity of angiotensin‑converting enzyme 2 (ACE2), known to be the receptor for SARS‑CoV‑2. Improved antiviral immunity by zinc may also occur through up‑regulation of interferon α production and increasing its antiviral activity. Zinc possesses …
Total citations
202020212022202320241212161658147
Scholar articles
AV Skalny, L Rink, OP Ajsuvakova, M Aschner… - International journal of molecular medicine, 2020